Novo Nordisk acquires German pharma in billion deal

Novo Nordisk has acquired German pharmaceutical company Cardior Pharmaceuticals in a deal potentially worth up to €1.025 billion, equivalent to 7.6 billion Danish kroner. This acquisition is contingent upon achieving certain commercial and development targets. Cardior specializes in treatments for cardiovascular diseases using RNA molecules to prevent, repair, and potentially cure heart diseases. The purchase aims to bolster Novo’s cardiovascular treatment pipeline. Cardior’s advanced drug candidate, CDR132L, is currently in phase 2 of the approval process. Novo Nordisk’s Development Director, Martin Holst Lange, praised Cardior’s scientific work, highlighting CDR132L’s unique mechanism and its potential to become a leading treatment that can stop or partially reverse the progression of heart diseases.